OMC Financial Services LTD Makes New Investment in Quest Diagnostics Incorporated $DGX

OMC Financial Services LTD purchased a new stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 3,279 shares of the medical research company’s stock, valued at approximately $695,000.

A number of other institutional investors have also modified their holdings of DGX. Key Financial Inc raised its stake in shares of Quest Diagnostics by 1,728.6% during the 1st quarter. Key Financial Inc now owns 128 shares of the medical research company’s stock worth $25,000 after acquiring an additional 121 shares in the last quarter. Quattro Advisors LLC acquired a new stake in Quest Diagnostics in the fourth quarter valued at approximately $25,000. DV Equities LLC acquired a new stake in Quest Diagnostics in the fourth quarter valued at approximately $27,000. Sittner & Nelson LLC purchased a new position in Quest Diagnostics in the fourth quarter worth $29,000. Finally, McIlrath & Eck LLC acquired a new position in shares of Quest Diagnostics during the fourth quarter worth $32,000. 88.06% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Evercore set a $225.00 price objective on Quest Diagnostics in a report on Tuesday, April 21st. Argus set a $260.00 target price on Quest Diagnostics in a research note on Wednesday, July 29th. Barclays upped their target price on Quest Diagnostics from $230.00 to $250.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. JPMorgan Chase & Co. increased their price target on Quest Diagnostics from $220.00 to $250.00 and gave the company a “neutral” rating in a research note on Tuesday, July 28th. Finally, Robert W. Baird raised their price target on Quest Diagnostics from $236.00 to $255.00 and gave the stock a “neutral” rating in a report on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat, Quest Diagnostics has an average rating of “Moderate Buy” and an average target price of $235.31.

Insider Activity at Quest Diagnostics

In other Quest Diagnostics news, SVP Mark E. Delaney sold 1,600 shares of the company’s stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $235.18, for a total value of $376,288.00. Following the sale, the senior vice president directly owned 10,335 shares of the company’s stock, valued at approximately $2,430,585.30. This represents a 13.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. E. Davis sold 10,000 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $194.14, for a total transaction of $1,941,400.00. Following the completion of the sale, the chief executive officer directly owned 132,423 shares in the company, valued at approximately $25,708,601.22. The trade was a 7.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 19,747 shares of company stock worth $3,947,088 over the last three months. Company insiders own 0.88% of the company’s stock.

Key Stories Impacting Quest Diagnostics

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Broad-based earnings estimate increases: Zacks Research raised its FY2026 EPS forecast to $11.15 from $10.66, FY2027 to $11.71 from $11.50, and FY2028 to $12.90 from $12.50. The firm also increased estimates for Q3 and Q4 2026, Q1 through Q3 2027, and Q1 and Q2 2028. These revisions suggest improving expectations for Quest Diagnostics’ earnings growth. MarketBeat analyst estimate updates
• Positive Sentiment: Momentum remains favorable: A Zacks analysis highlighted DGX’s 2.29% weekly gain and evaluated whether the stock can continue to attract momentum investors. The coverage may reinforce positive sentiment following the recent advance. Quest Diagnostics Is Up 2.29% in One Week
• Positive Sentiment: Dividend support: Quest Diagnostics declared a quarterly dividend of $0.86 per share, payable October 21 to shareholders of record October 6. The annualized yield is approximately 1.5%, providing ongoing shareholder income. Quest Diagnostics dividend announcement
• Neutral Sentiment: One estimate was lowered: Zacks reduced its Q4 2027 EPS forecast to $2.90 from $3.05, partially offsetting the otherwise positive revisions. The firm’s full-year 2027 and 2028 forecasts nevertheless remain higher than its previous estimates.

Quest Diagnostics Price Performance

Shares of NYSE:DGX opened at $234.48 on Monday. Quest Diagnostics Incorporated has a twelve month low of $171.18 and a twelve month high of $240.13. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.72. The company has a market cap of $25.88 billion, a PE ratio of 24.89, a price-to-earnings-growth ratio of 2.16 and a beta of 0.56. The company’s 50 day moving average is $215.60 and its 200 day moving average is $203.32.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $3.12 EPS for the quarter, beating the consensus estimate of $2.82 by $0.30. The business had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $2.97 billion. Quest Diagnostics had a net margin of 9.18% and a return on equity of 16.01%. The business’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the previous year, the business posted $2.62 EPS. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. On average, sell-side analysts forecast that Quest Diagnostics Incorporated will post 11.15 EPS for the current year.

Quest Diagnostics Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 21st. Investors of record on Tuesday, October 6th will be given a dividend of $0.86 per share. The ex-dividend date is Tuesday, October 6th. This represents a $3.44 dividend on an annualized basis and a yield of 1.5%. Quest Diagnostics’s payout ratio is currently 36.52%.

Quest Diagnostics Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.